Sentinel lymph node biopsy for staging breast cancer - 09/09/11

Doi : 10.1016/S0002-9610(98)00264-5

Isabel T Rubio, MD ^a, Soheila Korourian, MD ^b, Christopher Cowan, MD ^c, David N Krag, MD ^d, Maureen Colvert ^a : RNP, V.Suzanne Klimberg, MD ^a,^b,⁎
^a Department of Surgery, Division of Surgical Oncology (ITR, MC, VSK), University of Arkansas for Medical Sciences, Arkansas Cancer Research Center, John L. McClellan Veteran’s Administration Hospital, Little Rock, Arkansas, USA
^b Department of Pathology (SK, VSK), University of Arkansas for Medical Sciences, Arkansas Cancer Research Center, John L. McClellan Veteran’s Administration Hospital, Little Rock, Arkansas, USA
^c Department of Radiology (CC), University of Arkansas for Medical Sciences, Arkansas Cancer Research Center, John L. McClellan Veteran’s Administration Hospital, Little Rock, Arkansas, USA
^d Department of Surgery (DNK), University of Vermont, Burlington, Vermont, USA

^*Requests for reprints should be addressed to V. Suzanne Klimberg, MD, Department of Surgery, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 725, Little Rock, Arkansas 72205

Abstract

Background: Determination of axillary nodal status is essential for the staging of breast cancer since nodal status is one of the most important predictors of survival. The objective of this study was to test the hypothesis that the histology of the first draining lymph node (LN) accurately predicts the histology of the rest of the axillary LNs.

Methods: Fifty-five patients with operable invasive breast carcinoma and clinically negative axillary lymph nodes were studied. Patients were injected with Technetium-99 (⁹⁹Tc) sulfur colloid around the primary tumor. A hand-held gamma detector probe was used to identify the sentinel LN (SLN). After the SLN was identified and removed, a level I and II lymphadenectomy was performed.

Results: The SLN was identified in 53 (96.3%) of the 55 patients entered into the trial. The sensitivity was 88.2% and the specificity was 100%. The positive predictive value was 100% and the negative predictive value was 94.6%. The accuracy of the study was 96.2%.

Conclusions: The SLN biopsy for breast cancer staging is highly accurate in our hands and has the potential to decrease the morbidity and cost of managing patients with breast cancer without compromise of staging.

Le texte complet de cet article est disponible en PDF.

Plan

Materials and methods

This work was supported by NCI Grant U01 65121-02.

Export

Vol 176 - N° 6

P. 532-537 - décembre 1998 Retour au numéro

Article précédent

Sentinel lymph node biopsy, an alternative to elective axillary dissection for breast cancer
Fiemu E Nwariaku, David M Euhus, Peter D Beitsch, Edward Clifford, William Erdman, Dana Mathews, Jorge Albores-Saavedra, Marilyn A Leitch, George N Peters

| Article suivant

Management of casualties from the bombing at the Centennial Olympics
DavidV Feliciano, GailV Anderson, GraceS Rozycki, WalterL Ingram, JosephP Ansley, Nicholas Namias, JeffreyP Salomone, JohnD Cantwell

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Sentinel lymph node biopsy for staging breast cancer - 09/09/11

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL